These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27449546)

  • 21. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Pharmacist-Staffed, Virtual Gout Management Clinic for Achieving Target Serum Uric Acid Levels: A Randomized Clinical Trial.
    Goldfien R; Pressman A; Jacobson A; Ng M; Avins A
    Perm J; 2016; 20(3):15-234. PubMed ID: 27352414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
    Robinson PC; Taylor WJ; Dalbeth N
    J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
    Gandhi PK; Gentry WM; Ma Q; Bottorff MB
    J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving treat to target in gout: a clinical practice improvement project.
    Lim AY; Shen L; Tan CH; Lateef A; Lau TC; Teng GG
    Scand J Rheumatol; 2012; 41(6):450-7. PubMed ID: 22839705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N; Kumar S; Stamp L; Gow P
    J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
    Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
    Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-titration of allopurinol in patients with gout.
    Jennings CG; Mackenzie IS; Flynn R; Ford I; Nuki G; De Caterina R; Riches PL; Ralston SH; MacDonald TM;
    Semin Arthritis Rheum; 2014 Aug; 44(1):25-30. PubMed ID: 24560169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
    Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
    Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol.
    Day RO; Frensham LJ; Nguyen AD; Baysari MT; Aung E; Lau AYS; Zwar N; Reath J; Laba T; Li L; McLachlan A; Runciman WB; Buchbinder R; Clay-Williams R; Coiera E; Braithwaite J; McNeil HP; Hunter DJ; Pile KD; Portek I; WIlliams KM; Westbrook JI
    BMJ Open; 2017 Oct; 7(10):e017281. PubMed ID: 29042386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.
    Graham GG; Stocker SL; Kannangara DRW; Day RO
    Curr Rheumatol Rep; 2018 Jun; 20(8):47. PubMed ID: 29931553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
    Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
    Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Holland R; McGill NW
    Intern Med J; 2015 Feb; 45(2):189-94. PubMed ID: 25495503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.